Orkambi

(lumacaftor/ivacaftor)

- Drug used in the treatment of Cystic Fibrosis
- transmembrane conductance regulator potentiator
- Approved for ages 2 and older
- Review Article

Cataracts with Lumacaftor/Ivacaftor

- Cataracts were found in juvenile rats in pre-clinical toxicology studies
- Cataracts have been discovered in a few children taking this drug. The concomitant use of steroids or other pre-existing coniditions could not be excluded.
 - Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
 - The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review
- Drug manufacturer recommends baseline and follow-up eye examinations of unspecified interval or duration
 - Prescribing Information

drugs

From: https://childrenseye.org/wiki/ - **Children's Eye Wiki**

Permanent link: https://childrenseye.org/wiki/doku.php?id=orkambi

Last update: 2021/04/04 22:19

